Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. Weinstock-Guttman B, Hagemeier J, Kavak KS, Saini V, Patrick K, Ramasamy DP, Nadeem M, Carl E, Hojnacki D, Zivadinov R J Neurol Neurosurg Psychiatry. 2016 Jan 18. PMID: 26780938. Abstract CommentRecommendBookmarkWatch